DOTATATE PET for Meningioma Radiation Planning (NCT06937268)
Exploratory Analysis of DOTATATE PET for Meningioma Radiation Planning
🩺 Plain-English Summary (8th-Grade Level)
68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET
Who can join: Review the eligibility criteria below.
Location: BC Cancer - Vancouver — Vancouver, British Columbia
Age range: 18 Years
🧪 Interventions in This Study
- DOTATATE-PET scan (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- BC Cancer - Vancouver — Vancouver, British Columbia
📞 Contact the Study Coordinator
Phone: (604) 877-6000
Email: sandy.chang@bccancer.bc.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Meningioma
- Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas — Chicago, Illinois
- A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas — Boston, Massachusetts
- Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma — New York, New York
- Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC — New York, New York
- A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma — San Francisco, California
Explore by condition: All Meningioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.